In the last decade, immunotherapy, including PD-L1/PD-1 immunecheckpoint blockade, has emerged as a promising therapeutic strategy in the treatment of different solid tumors and some hematological malignancies as Hodgkin lymphoma (4). Here, PDCD1 is linked to hematologic disorder.